Acquired resistance to PRMT5 inhibition induces concomitant collateral sensitivity to paclitaxel
Mueller H, Fowler C, Dalin S, Moiso E, Udomlumleart T, Garg S, Hemann M, Lees J. Acquired resistance to PRMT5 inhibition induces concomitant collateral sensitivity to paclitaxel. Proceedings Of The National Academy Of Sciences Of The United States Of America 2021, 118: e2024055118. PMID: 34408017, PMCID: PMC8403834, DOI: 10.1073/pnas.2024055118.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinoma of LungAnimalsAntineoplastic AgentsCell Line, TumorCell ProliferationDrug Resistance, NeoplasmDrug SynergismEpigenesis, GeneticGene Expression Regulation, NeoplasticGene Knockdown TechniquesHumansLung NeoplasmsMiceMutationPaclitaxelProtein-Arginine N-MethyltransferasesStathminConceptsProtein arginine methyltransferase 5Stathmin-2Sensitivity to paclitaxelPRMT5 inhibitorsLung adenocarcinomaPRMT5 inhibitionResponse to taxane treatmentCell linesArginine methyltransferase 5Resistance to inhibitorsRegression of tumorsMicrotubule regulationLung adenocarcinoma lineAcquisition of resistanceCancer cell linesPotential clinical relevanceEpigenetic regulationHuman cancer cell linesBarcoding experimentsMechanisms of resistanceTaxane treatmentPreexisting populationTaxanes paclitaxelCollateral sensitivityLung adenocarcinoma cells
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply